Key result
Benidipine was as effective as atenolol in reducing cardiovascular events in post-myocardial infarction patients, with no significant difference in the primary composite outcome.
Why the study?
Does benidipine reduce cardiovascular events compared to atenolol in post-MI patients without vasospastic angina?
RCT (n=120)
Open-label
randomly assigned
Yes
Does benidipine reduce cardiovascular events compared to atenolol in post-MI patients without vasospastic angina?
Answers are grounded in this paper and cite their sources.
BACKGROUND: Beta-blockers (BB) have been widely used in the management of hypertension and acute myocardial infarction (AMI), and both national and international guidelines have recommended them as first-line agents. Calcium channel antagonists (CCA) are also effective in the treatment of hypertension and angina pectoris. However, the efficacy of CCA in the prevention of cardiovascular events in post-myocardial infarction (MI) patients in comparison to that of BB remains unclear. METHODS AND RESULTS: A total of 120 post-MI patients (71 patients who were at least 1 month after the onset AMI and 49 stable coronary artery disease patients with a history of MI) were randomly assigned to receive a BB (atenolol, 25-50mg/day, n=60) or a CCA (benidipine, 4-8 mg/day, n=60). All patients with AMI within the previous 1 month or with vasospastic angina were excluded from the present study. The baseline clinical characteristics were generally similar in the BB and CCA groups. The rate of primary composite outcome was 26.3% in the BB group in comparison to 13.3% in the CCA group, with no significant between-group differences (hazard ratio with the CCA group 0.640, P=0.276). Both treatments were well tolerated with few severe adverse events. CONCLUSIONS: CCA treatment was found to be as effective as BB in reducing cardiovascular events in post-MI patients.
No takes yet. Share an insight, caveat, or question.
Nakagomi et al. (2011) conducted an RCT in Post-myocardial infarction (n=120). Benidipine vs. Atenolol 25-50 mg/day was evaluated on Composite of death from cardiovascular events, new onset of angina pectoris and silent myocardial ischemia requiring PCI, or target lesion revascularization (HR 0.64, 95% CI 0.284-1.440, p=0.276). Benidipine was as effective as atenolol in reducing cardiovascular events in post-myocardial infarction patients, with no significant difference in the primary composite outcome.
Synapse has enriched 10 related papers. Consider them for comparative context: